Search 

Precision NanoSystems Inc. (“PNI”) has developed proprietary technology (NanoAssemblr) and companion Reagent Kits (SUB9KITS) that enable the simple manufacture of novel nanoparticles that are used to delivery genetic and small molecule medicines (nanomedicines). Nanomedicines are the "FedEx" of the health-care industry and are used for cell-specific delivery of research tools, diagnostic imaging agents and drugs to study, diagnose and treat disease. PNI's products are commercialized and in high demand from many of leading RNA and small molecule therapeutic biotechnology and pharmaceutical companies.  http://www.precisionnanosystems.com/products/

Prize4Life is a non-profit organization founded in 2006 in Cambridge, MA focused on accelerating therapy development for amyotrophic lateral sclerosis (ALS, aka Lou Gehrig's disease). Prize4Life uses incentive prizes to attract new minds and drive innovation in ALS drug development. The organization is running the $1M Avi Kremer ALS Treatment Prize4Life challenge for preclinical validation of a novel ALS therapeutic in an ALS mouse model, and submissions to this prize will be accepted until June 6th 2015. In addition to prizes, Prize4Life also runs infrastructure programs to support the ALS research community, such as the ALS FORUM, an online portal of cutting edge research and drug development news in ALS (www.researchals.org).

RCT Ventures invests in early-stage life science companies including medical devices, drug discovery platforms, and research tools.

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.

F. Hoffmann-La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche is looking for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionize the standard of care. Roche focuses on their main disease therapy areas – oncology and Immuno-oncology, ophthalmology, infectious diseases and neurosciences–as well as looking at opportunities in promising technologies and early-stage collaborations. Beyond the asset, Roche always look for the right partnership and cultural fit. Roche also seeks collaboration in diagnostics, specifically biomarkers.

SENS Research Foundation is based in Mountain View, CA. The foundation provides grants for research into rejuvenation biotechnologies that prevent or reverse age-related tissue damage. Historically grants have ranged from $40,000 to $200,000 although this range may change in the future. Grants are available to researchers worldwide. SENS requests that grants not be used to cover overhead/facilities costs. At present, 15 projects are being supported.

Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

Shire is an Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft. 

Shire is currently interested in several therapeutic areas for business development opportunities. The company is most interested in the following products: rare disease therapeutics, pre-clinical to on the market; neuroscience therapeutics, on the market; gastrointestinal, on the market; ophthalmology, post proof-of-concept; and hematology; post proof-of-concept.